| Company/Division name | Regenxbio |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 200 |
| Year reshoring implemented or to be implemented: | 2022 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 100 |
| City reshored to: | Rockville |
| State(s) reshored to: | MD |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | gene therapy |
| What non-domestic negative factors made offshoring less attractive? | Quality/rework/warranty |
| What domestic positive factors made reshoring more attractive? | Higher productivity |
